In patients presenting with clinically localized prostate cancer, the risk of biochemical failure increases significantly with higher Gleason scores, prostate specific antigen (PSA) levels, and clinical stages. Current surgical and radiotherapeutic approaches appear to offer limited success in patients with highly adverse prognostic factors. In an attempt to improve on these outcomes, we have combined external beam radiotherapy (EBRT) with a brachytherapy (BT) boost and neo adjuvant and adjuvant androgen ablation in a population at significant risk of biochemical failure. Here we present early biochemical progression data for this approach. From October 1997 to July 1999, 72 men with a serum PSA 10 ng/ml or Gleason score 7 or clinical stage T2c (AJC/UICC 1992) underwent EBRT followed by palladium-103 BT. All patients underwent 8 months of combined androgen ablation with leuprolide and an oral antiandrogen beginning 3 months prior to initiation of EBRT. Patients were followed by PSA and digital rectal examination (DRE) at 3-month intervals and a chart review on all patients was carried out during July 2001. To allow comparisons to contemporary literature, Kaplan-Meier survival curves were generated utilizing three alternate definitions of biochemical recurrence: PSA > 0.2 ng/ml, PSA > 1.0 ng/ml, and the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus definition of three consecutive rising PSAs. Our results indicate that when PSA > 0.2 ng/ml was used to define biochemical progression, 88% (95% CI 80 -97) of patients remained free of disease at 24 months. When PSA > 1.0 ng/ml was used, 97% (CI 92 -100) of patients remained disease free at 24 months. ASTRO criteria yielded 90% (CI 82 -98) recurrence-free survival at 24 months. In conclusion, this very early report indicates that in patients who are at increased risk of biochemical failure, EBRT with a BT boost in conjunction with short-term androgen ablation offers potentially superior biochemical disease-free survival to contemporary alternative approaches in the literature. Clearly, longer followup is required to confirm the durability of this approach.
Introduction
Adenocarcinoma of the prostate will be diagnosed in 180 000 men in the year 2000. 1 The widespread use of prostate specific antigen (PSA) and digital rectal exam (DRE) screening has allowed the detection of many clinically organ confined tumors; however, many men still present with locally advanced tumors. Currently, such men have several potentially curative treatment options, including radical prostatectomy (RP), 2 external beam radiotherapy (EBRT), 3 combination of EBRT and brachytherapy (BT) 4 and cryotherapy. 5 While surgical therapy remains the gold standard for patients with early disease, the risk of PSA recurrence increases significantly in patients with serum PSA > 10 ng/ml, Gleason scores 7 -10, and clinical stage T2c and above. 2, 6, 7 A review of 440 patients with pretreatment PSA > 10 ng/ml revealed only 49% biochemical progression-free survival at 7 y. 6 Another large cohort of patients with pathological stage T3 prostate cancer revealed 46% biochemical progression-free survival at 10 y. 8 The dilemma of effective treatment for locally advanced prostate cancer is complicated by the finding that 78% of the above-mentioned pT3 prostate cancers were clinical stage T2, suggesting that patients are not infrequently understaged.
While a RP offers definitive control of intraprostatic adenocarcinoma, it is less capable of addressing extraprostatic spread in advanced tumors even in conjunction with neoadjuvant androgen ablation. 9 Similarly, the high radiation dose delivered to the prostate by brachytherapy might offer good control of intraprostatic tumor while allowing small tumor foci outside the prostate to persist. Conversely, EBRT to the periprostatic area may sterilize locally advanced tumor deposits but may potentially not deliver a lethal dose to the intraprostatic tumors, which can be significant in volume. Neoadjuvant and adjuvant androgen ablation in the context of EBRT has been shown to improve local control and PSA recurrence rate 10 -12 and may act by reducing tumor volume and/or sensitizing the tumor to radiation among many other possible mechanisms. While the duration of neoadjuvant and adjuvant androgen ablation is still debated, it would appear that 6 -8 months is superior to shorter intervals. 10 A recent comparison of various treatment modalities for localized prostate cancer including RP, EBRT, brachytherapy, and brachytherapy combined with androgen ablation highlights the deficiencies of these techniques in the patients at high risk for biochemical failure. 13 In fact, in these patients, actuarial biochemical failure rates, defined by the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus definition, 14 for the four therapies ranged from 15 to 50% for intermediate risk patients, and from 40 to 90% in high risk patients at 2 y.
In an attempt to improve on these outcomes we have elected to treat patients with locally advanced cancers with triple modality therapy. EBRT is followed by brachytherapy boost in the context of 8 months of neoadjuvant and adjuvant androgen ablation. An interstitial brachytherapy boost following EBRT has the theoretical advantage of delivering higher tissue doses than EBRT alone while benefiting from the periprostatic irradiation offered by the EBRT component. 4 Thus, more advanced cancers, having larger volumes of disease and higher probability of extraprostatic extension 15 may perhaps be more effectively treated. For these patients we selected palladium-103 as the BT isotope of choice in view of its higher dose rate 16 and theoretical advantages in sterilizing more rapidly growing tumors. The goal of this study is to report our early results with this combination therapy in high-risk patients and to compare these results to several large series, with similar risk patients. In addition, in order to facilitate such comparisons as well as highlight the differences in failure rates obtained with various endpoints, we have analyzed the data with three such commonly employed definitions.
Methods

Study population
From October 1997 to July 1999, 289 men with clinical stage T1c -T3 17 adenocarcinoma of the prostate underwent treatment with palladium-103 BT at a tertiary care university hospital. Patients were stratified to treatment strategy based on their PSA, biopsy Gleason score and clinical stage. Seventy-two patients with PSA 10 ng/ml, Gleason score 7, or clinical stage T2c 17 received combination BT and EBRT with combined androgen blockade while all others (n ¼ 217) underwent BT monotherapy. 18 The 72 patients undergoing combination therapy underwent bone scan and computerized tomography staging prior to treatment to ensure clinical stage N0M0 disease and comprise the study population. A chart review on these patients was carried out in July 2001 to evaluate clinical status and last PSA value. To facilitate comparison with the current literature, these patients were stratified into 'intermediate-risk' (PSA 20 ng/ml and stage T2b and Gleason score 7) or 'high-risk' (PSA > 20 ng/ml or stage T2c or Gleason score > 7). 13 
Brachytherapy techniques
Three attending urologists in conjunction with two radiation oncologists planned and performed the brachytherapy procedures. Our combined EBRT þ BT protocol is outlined in Figure 1 . Due to evidence that neoadjuvant hormonal deprivation enhances disease-free survival in EBRT for locally advanced prostate cancer, 11, 12 all patients underwent 8 months of combined androgen ablation with an LHRH (luteinizing hormone releasing hormone) agonist (leuprolide) and oral antiandrogen (bicalutamide or flutamide). External beam therapy of 40 -45Gy over 6 weeks began 2 -3 months after initiation of androgen blockade.
Brachytherapy was performed approximately 4 -6 weeks after completion of EBRT. A planning transrectal ultrasound was obtained in the outpatient clinic 2 -3 weeks prior to the BT procedure and analyzed using the MMS TherpacPLUS B3DTUI software (Multimedia Medical Systems Inc. Charlottesville, VA, USA). All patients were treated with palladium-103 permanent interstitial implants to a prescribed dose of 90 Gy. Percutaneous transperineal implantation was carried out after the manner described by Sylvester et al. 19 With the patient in dorsal lithotomy position under general anesthesia, the transrectal ultrasound with perineal implant template was carefully positioned to recreate the planning ultrasound. Transperineal 18 gauge preloaded needles were inserted into the prostate under ultrasonic guidance according to the previously generated plan. Post-implant dosimetry was carried out by analysis of images obtained by computerized tomography of the prostate within 24 h following implantation using the MMS software. An additional 3 months of androgen ablation followed implantation, resulting in a total of 8 months of androgen ablation.
Follow-up and study endpoints
Patients were scheduled for follow-up with PSA and DRE on a 3-month interval. Because the definition of biochemical recurrence has been controversial, 4, 20 we performed separate calculations utilizing three popular definitions of biochemical recurrence: PSA > 0.2 ng/ml, 4 PSA > 1.0 ng/ml, 21 and the American Society for Therapeutic Radiology and Oncology (ASTRO) guidelines which define biochemical progression as three successive rising PSAs. 14 Finally, because approximately 35% of patients undergoing radiotherapy experience a 'PSA bounce' 22 consisting of an increase of 0.1 ng/ml above the preceding PSA level followed by a decrease below that level, we also provided results with and without bounce correction for PSA endpoints > 0.2 ng/ml and > 1.0 ng/ml. Time to treatment failure was defined as time from brachytherapy to biochemical failure.
Statistical methods
Summaries of failure are expressed as number and per cent within categories representing clinical stage, Gleason score and baseline PSA. Categories were generated to be consistent with the literature and achieve approximately equal group sizes when possible. Survival estimates and 95% confidence intervals (95% CI) were generated and plotted for time to biochemical recurrence using the Kaplan-Meier method.
Results
Patient and tumor characteristics
The median age of the 72 men who underwent treatment was 68.5 y old (range 48.8 -80.5). Three (4.2%) men were African-American, while the remainder were Caucasian. The median pre-treatment PSA for the study population was 9.2 (range 0.6 -45.9) ng/ml. The median pre-treatment PSA for the intermediate risk subset was 7.8 ng/ml, while the median PSA for the high risk group was 10.3 ng/ml. The tumor characteristics by PSA, Gleason score, and clinical stage are listed for both groups in Table 1 .
Survival analysis
Median follow-up for the whole patient population was 28.3 months (range 1.0 -43.4). In the intermediate risk group (PSA 20 ng/ml and Gleason 7 and clinical stage T2b), only one biochemical recurrence (4%) was seen with PSA > 0.2, none with PSA > 1.0 ng/ml, and 4 (17%) by ASTRO criteria (Table 2 ).
In the high risk group (stage T2c, PSA 20 ng/ml or Gleason 8) the PSA cut-off of 0.2 ng/ml yielded 12 (25%) biochemical failures among 48 patients, but the use of bounce correction reduced the number of failures to nine (19%; Table 2 ). The Kaplan-Meier survival curves for the entire group of 72 patients utilizing PSA > 0.2 ng/ ml are seen in Figure 2A (without bounce correction) and in Figure 2C (with bounce correction). Utilizing PSA > 0.2 ng/ml with bounce correction as the definition of biochemical recurrence, the 24-month recurrence-free survival was 88.0% (95% CI 80.1 -96.8%), while the bounce corrected survival was 91.6% (CI 84.7 -99.7). The use of PSA > 1.0 ng/ml as the definition of biochemical recurrence yielded only three recurrences in 48 patients (4%), but this recurrence was seen in only one patient (2%) when the bounce correction was added ( Table 2 ). The 24-month recurrence-free survival was 96.7% (CI 92.3 -100.0) using PSA > 1.0 ng/ml as the definition of biochemical recurrence. Bounce correction yielded no recurrences (100% recurrence-free survival) by this definition within 24 months. The Kaplan-Meier survival curves utilizing PSA > 1.0 ng/ml are seen in Figure 2B (without bounce correction) and Figure 2D (with bounce correction). When ASTRO criteria are used in our study population, seven patients (10%) meet criteria for biochemical disease recurrence ( Figure 2E ). This number was not changed by bounce correction. In summary, use of the less stringent ASTRO criteria in all our patients yields 89.8% (CI 82.4 -97.9) biochemical recurrence-free survival at 24 months.
Discussion
D'Amico and colleagues compared biochemical disease free survival in palladium-103 BT with and without neoadjuvant hormone ablation to RP and to EBRT. 13 Patients were stratified as low, intermediate, or high risk for post therapy PSA failure based on pre-therapy PSA level, biopsy Gleason scores and clinical stage. Biochemical failure was assessed using the ASTRO criteria. In low risk patients (T1c or T2a, PSA 10 ng/ml, and Gleason score 6) there was no significant difference in outcome noted across all treatment modalities. Intermediate risk patients (T2b, PSA 10 -20 ng/ml, or Gleason score 7) fared worse with BT than RP if BT was used alone, but the addition of androgen deprivation to BT provided outcomes equivalent to RP. In high-risk patients (stage T2c, PSA 20 ng/ml, or Gleason 8), BT patients exhibited higher rates of PSA recurrence than with RP, even in patients who received neoadjuvant hormone ablation in conjunction with BT. 13 A review of the Kaplan-Meier curves published in that study reveals approximately 58% biochemical diseasefree survival for their intermediate-risk group with BT and androgen ablation while our very similar intermediate-risk cohort has 0% by the same ASTRO criteria used in that study ( Figure 2 , Table 2 ). The contrast is even more marked when our high-risk cohort is compared to the very poor outcomes seen in the high-risk group of D'Amico and colleagues, which approaches 10% disease-free survival at 2 y when treated with BT with or without androgen ablation. Using the ASTRO criteria, we show a 90% biochemical disease-free survival in this group. Even utilizing the more rigorous definition of PSA > 0.2 ng/ml in our data yields 88% biochemical recurrence-free survival at 24 months for all patients, which is markedly better than the D'Amico data.
Ragde and colleagues have published 12-y observed biochemical disease free survival data for iodine-125 brachytherapy. 23 Patients with stage T2b disease or with Gleason score 7 were felt to have significant risk of extracapsular extension and were therefore treated with 45 Gray EBRT prior to iodine-125 BT. The mean PSA in this group was 14.7 ng/ml and no patient received androgen ablation. Using the ASTRO definition of biochemical failure, a review of the Kaplan-Meier curves reveals 2-y disease-free survival of approximately 85%. (8) 8 (3) 8 (3) 17 (6) 3 (1) PSA (ng/ml) < 10 37 11 (4) 0 (0) 11 (4) 8 ( (12) 6 (3) 6 (3) 19 (9) 2 (1) Overall 72 18 (13) 4 (3) 1 (7) 14 (10) 1 (1) a As defined in reference 17 b
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Multimodality radiotherapy in high risk prostate cancer TR Coblentz et al
In our 'high risk' patient cohort, which contained patients with more aggressive tumors, we had a 90% recurrencefree survival by the ASTRO criteria at 2 y. Critz and colleagues 4 have recently published intermediate term outcome data on a large cohort of men with early stage prostate cancer who underwent transperineal iodine-125 brachytherapy followed 3 weeks later by EBRT. Pretreatment PSA were 10 -20 ng/ml in 21%, > 20 in 6% of patients respectively, while Gleason scores were 7 in 19% and 8 -10 in 4% of patients. Twenty per cent of patients were clinical stage T2b while 8% were T2c, (no neoadjuvant androgen ablation was utilized and biochemical progression was defined as PSA > 0.2 ng/ ml). The actuarial 2-y disease-free rate of patients with pretreatment PSA of 10 -20 ng/ml was approximately 85% while this rate dropped to 80% in patients with PSA > 20 ng/ml. Although these results are excellent, it must be noted that 96% of entire group had Gleason scores 7. In contrast, we had one (4%) biochemical failure in an equivalent (intermediate-risk) group (Table  2 ) using the same definition of PSA failure. In addition, we had similar biochemical failure at 2 y in patients with more aggressive 'high-risk' disease.
Many centers use neoadjuvant androgen ablation for cytoreduction in large glands to reduce prostate volume, reduce pubic arch interference, or to reduce the number of seeds required. Other centers prescribe androgen ablation in higher risk patients in hopes of improving the efficacy of radiotherapy. In a retrospective matched-pairs analysis of 263 brachytherapy patients, Potters and colleagues were unable to detect any improvement in disease free survival when neoadjuvant androgen ablation was added to brachytherapy. 24 However it is possible that low recurrence rates in a low risk patient group decreased the power to detect a significant difference. Conversely, two studies have shown that androgen ablation does benefit patients with locally advanced prostate cancer treated with EBRT, and our decision to prescribe androgen ablation to this high risk cohort was based primarily on the fact that these patients were receiving EBRT as a component of the protocol. A Radiation Therapy Oncology Group (RTOG) Phase III trial of androgen suppression with an LHRH analog in conjunction with external beam radiotherapy for patients with clinical stage T1-2 prostate cancer with involved lymph nodes or stage T3 prostate cancer documented lower incidence of local and distant failure and higher biochemical disease-free survival at 5 y in the arm receiving androgen ablation. The positive effect of androgen ablation on biochemical disease free survival appeared more prominent in high-grade Gleason scores (Gleason 8 -10). In addition, patients with Gleason 8 -10 tumors had statistically significant higher overall survival rates when treated with androgen ablation. 11 A similar randomized prospective trial by Bolla and colleagues in patients with predominantly clinical stage T3 disease also showed a significant survival benefit to a 3-y course of goserelin which began at the start of EBRT. 12 A third prospective trial open to both low-and high-risk patients by Laverdiere and colleagues 10 randomized patients undergoing EBRT into three groups: a control group with no hormonal manipulation, a group which underwent 3 months of combined androgen ablation prior to EBRT, and a third group which underwent androgen ablation 3 months before, during, and 6 months after EBRT. Prostate biopsies 24 months after EBRT revealed residual cancer in 65, 28 and 5% of the three groups respectively. The latter study played a role in our selection of a longer duration of androgen ablation, and we therefore prescribed 2 -3 months prior to EBRT and 5 -6 months after EBRT (Figure 1) .
We chose to treat with palladium-103 in this subset of patients primarily because in vitro radiobiological data suggests that this isotope may be more effective in more rapidly divided tumors. 16 Clinically, the choice of palladium-103 vs iodine-125 interstitial implants has been investigated by Cha and colleagues. 25 Despite subgroup analysis based on Gleason scores and pretreatment PSA, there were no observed advantages for either isotope in a retrospective matched pair analysis of 222 patients but this may be due to insufficient power to detect differences in this very favorable group of patients. An additional reason for our choice of palladium-103 was that it would decay completely while the patient was undergoing androgen ablation and thus take full advantage of the potential for radiosensitization this treatment may offer.
In conclusion, we have presented early data on an aggressive combination of external beam radiotherapy with palladium-103 brachytherapy boost during combined neoadjuvant and adjuvant androgen blockade. Using multiple definitions of biochemical failure, at the 2-y mark, this triple therapy approach appears to offer some early advantages over popular monotherapy (that is, RP, BT, EBRT) or dual therapy (that is, BT þandrogen ablation, EBRT þandrogen ablation, BT þ EBRT) approaches in patients with high-risk prostate cancer.
